Key facts
- It has raised $140K; the latest was PE Growth/Expansion in May 2025.
- Notable investors include Techstars, StoryHouse Ventures, African Union Development Agency-NEPAD, Nubia Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Syndicate Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Syndicate Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Syndicate Bio
Operator of a biotechnology research company focused on leading precision medicine initiatives in diverse geographical regions. The company uses large-scale partnerships with governments and other stakeholders to drive local precision medicine impact while creating powerful datasets that can be used for drug discovery and development, enabling researchers to make advancements in global genomics science.
- Sector
- Healthcare
- HQ
- Newark, DE, United States
- Founded
- 2023
- Employees
- 8
- Website
- syndicate.bio/
- Ownership
- Privately Held (backing)
Syndicate Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Syndicate Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Syndicate Bio in its N-PORT filings yet. We sweep new filings monthly.